Literature DB >> 1315309

Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: a model for the study of molecular mimicry in the pathogenesis of viral myocarditis.

C M Lawson1, H L O'Donoghue, W D Reed.   

Abstract

Mouse cytomegalovirus (MCMV) infection induces persisting myocarditis in the susceptible BALB/c strain. Autoantibodies to cardiac myosin are produced in both susceptible BALB/c and resistant C57BL/6 mice following MCMV infection. These affinity-purified anti-cardiac myosin antibodies cross-react with MCMV protein(s). The polypeptides of CMV which share immunological cross-reactivity with the 200,000 MW polypeptide, the heavy chain of myosin, were viral polypeptides of 83,000, 94,000 and 116,000 MW recognized by BALB/c post-infection sera and polypeptides of 66,000 and 94,000 MW recognized by C57BL/6 post-infection sera. Passive transfer of anti-cardiac myosin antibodies from Day 56 post-infection sera of the BALB/c strain induced inflammation and necrosis of the myocardium of uninfected BALB/c recipients. This late immune sera contains autoantibodies specific for the cardiac isoform of myosin. Furthermore, immunization with cardiac myosin induced myocarditis and high titres of cardiac myosin antibodies in uninfected mice of the susceptible BALB/c strain only. However, antibodies to myosin elicited in cardiac myosin-immunized BALB/c mice did not cross-react with MCMV by ELISA. We suggest that virus infection may modulate the immune recognition of the common-epitope(s) shared between MCMV protein(s) and the heavy chain of myosin. Of particular interest is the possibility that molecular mimicry of CMV with cardiac myosin may contribute to the pathogenesis of autoimmune myocarditis following virus infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315309      PMCID: PMC1384748     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  CYTOMEGALIC INCLUSION DISEASE IN PATIENTS WITH ACUTE LEUKEMIA.

Authors:  G P BODEY; P T WERTLAKE; G DOUGLAS; R H LEVIN
Journal:  Ann Intern Med       Date:  1965-05       Impact factor: 25.391

2.  Delayed-type hypersensitivity responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice.

Authors:  C M Lawson; J E Grundy; G R Shellam
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

3.  Autoimmune diseases: the failure of self tolerance.

Authors:  A A Sinha; M T Lopez; H O McDevitt
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

4.  Monoclonal antibody to coxsackievirus B4 reacts with myocardium.

Authors:  J Saegusa; B S Prabhakar; K Essani; P R McClintock; Y Fukuda; V J Ferrans; A L Notkins
Journal:  J Infect Dis       Date:  1986-02       Impact factor: 5.226

5.  T cell lines selected with synthetic peptides are highly encephalitogenic in SJL/J mice.

Authors:  D N Bourdette; A A Vandenbark; G Hashim; R H Whitham; H Offner
Journal:  J Neuroimmunol       Date:  1989-05       Impact factor: 3.478

6.  Molecular mimicry and autoimmune disease.

Authors:  M B Oldstone
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

7.  Immunoblot analysis of the antibody response to murine cytomegalovirus in genetically resistant and susceptible mice.

Authors:  H E Farrell; G R Shellam
Journal:  J Gen Virol       Date:  1989-10       Impact factor: 3.891

8.  Cytomegalovirus myocarditis.

Authors:  K Wink; H Schmitz
Journal:  Am Heart J       Date:  1980-11       Impact factor: 4.749

9.  Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity.

Authors:  C M Lawson; H L O'Donoghue; H E Farrell; G R Shellam; W D Reed
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

10.  Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens.

Authors:  S A Huber; P A Lodge
Journal:  Am J Pathol       Date:  1984-07       Impact factor: 4.307

View more
  29 in total

1.  Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease.

Authors:  S K Ray; C Putterman; B Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

2.  Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice.

Authors:  J C Lenzo; G R Shellam; C M Lawson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  A novel murine model of differentiation-mediated cytomegalovirus reactivation from latently infected bone marrow haematopoietic cells.

Authors:  Xue-Feng Liu; Suchitra Swaminathan; Shixian Yan; Flora Engelmann; Darryl Adelaide Abbott; Luke Andrew VanOsdol; Taylor Heald-Sargent; Longhui Qiu; Qing Chen; Andre Iovane; Zheng Zhang; Michael M Abecassis
Journal:  J Gen Virol       Date:  2019-12       Impact factor: 3.891

Review 4.  Unresolved issues in theories of autoimmune disease using myocarditis as a framework.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  J Theor Biol       Date:  2014-12-04       Impact factor: 2.691

5.  Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

Authors:  Charles C Chu; Rosa Catera; Katerina Hatzi; Xiao-Jie Yan; Lu Zhang; Xiao Bo Wang; Henry M Fales; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

6.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

7.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

8.  Lymphocytes protect against and are not required for reovirus-induced myocarditis.

Authors:  B Sherry; X Y Li; K L Tyler; J M Cullen; H W Virgin
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

Review 9.  An approach to the treatment of pediatric myocarditis.

Authors:  Daniel Levi; Juan Alejos
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 10.  Antiviral immune responses: triggers of or triggered by autoimmunity?

Authors:  Christian Münz; Jan D Lünemann; Meghann Teague Getts; Stephen D Miller
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.